APA (7th ed.) Citation

Fogel, L., Roney, P. C., Ahn, J., Aleman, A., Perez-Manon, F., Arias-Orozco, N., . . . Biran, N. (2026). Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: A single center experience. Leukemia & Lymphoma, 67(2), 366. https://doi.org/10.1080/10428194.2025.2592783

Chicago Style (17th ed.) Citation

Fogel, Lindsay, et al. "Real-world Outcomes of Patients with Relapsed Refractory Multiple Myeloma Treated with Commercial Bispecific T-cell Engager Antibodies: A Single Center Experience." Leukemia & Lymphoma 67, no. 2 (2026): 366. https://doi.org/10.1080/10428194.2025.2592783.

MLA (9th ed.) Citation

Fogel, Lindsay, et al. "Real-world Outcomes of Patients with Relapsed Refractory Multiple Myeloma Treated with Commercial Bispecific T-cell Engager Antibodies: A Single Center Experience." Leukemia & Lymphoma, vol. 67, no. 2, 2026, p. 366, https://doi.org/10.1080/10428194.2025.2592783.